Kymera Therapeutics Net Income vs. Cash And Equivalents
| KYMR Stock | USD 45.02 0.03 0.07% |
Net Loss | First Reported 2019-09-30 | Previous Quarter -42.1 M | Current Value -62.5 M | Quarterly Volatility 16 M |
For Kymera Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kymera Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kymera Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kymera Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kymera Therapeutics over time as well as its relative position and ranking within its peers.
Kymera |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kymera Therapeutics. If investors know Kymera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kymera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.34) | Revenue Per Share 1.258 | Quarterly Revenue Growth (0.21) | Return On Assets (0.15) | Return On Equity (0.26) |
The market value of Kymera Therapeutics is measured differently than its book value, which is the value of Kymera that is recorded on the company's balance sheet. Investors also form their own opinion of Kymera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kymera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kymera Therapeutics' market value can be influenced by many factors that don't directly affect Kymera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kymera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kymera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kymera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kymera Therapeutics Cash And Equivalents vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kymera Therapeutics's current stock value. Our valuation model uses many indicators to compare Kymera Therapeutics value to that of its competitors to determine the firm's financial worth. Kymera Therapeutics is rated fourth overall in net income category among its peers. It is rated below average in cash and equivalents category among its peers . Kymera Therapeutics reported last year Net Loss of (146.96 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Kymera Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Kymera Cash And Equivalents vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Kymera Therapeutics |
| = | (146.96 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Kymera Therapeutics |
| = | 392.31 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Kymera Cash And Equivalents Comparison
Kymera Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Kymera Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kymera Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kymera Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Kymera Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Kymera Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -552 K | -579.6 K | |
| Net Interest Income | 18.6 M | 19.5 M | |
| Interest Income | 18.8 M | 19.7 M | |
| Operating Income | -165.5 M | -157.3 M | |
| Net Loss | -147 M | -139.6 M | |
| Income Before Tax | -147 M | -139.6 M | |
| Total Other Income Expense Net | 18.6 M | 19.5 M | |
| Net Loss | -139.3 M | -132.4 M | |
| Net Loss | -147 M | -139.6 M | |
| Income Tax Expense | 18.8 M | 19.7 M | |
| Non Operating Income Net Other | 7.4 M | 7.8 M | |
| Change To Netincome | 40.8 M | 42.8 M | |
| Net Loss | (2.52) | (2.64) | |
| Income Quality | 0.70 | 0.73 | |
| Net Income Per E B T | 1.13 | 1.08 |
Kymera Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kymera Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kymera Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kymera Therapeutics' important profitability drivers and their relationship over time.
Use Kymera Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Kymera Therapeutics Pair Trading
Kymera Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Kymera Therapeutics position
In addition to having Kymera Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Monster Funds Thematic Idea Now
Monster Funds
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.